Beyond RSWA in prodromal α-synuclein disease: Do periodic limb movements signal potential early dopaminergic dysfunction?
Beyond RSWA in prodromal α-synuclein disease: Do periodic limb movements signal potential early dopaminergic dysfunction?
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Davis, US · Author affiliation
Department of Neurology/Division of Sleep Medicine, University of California Davis, Sacramento, CA, USA. Electronic address: sgorantla@health.ucdavis.edu.Location evidence
Sacramento, US · Author affiliation
Department of Neurology/Division of Sleep Medicine, University of California Davis, Sacramento, CA, USA. Electronic address: sgorantla@health.ucdavis.edu.Location evidence
Innsbruck, AT · Author affiliation
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.Location evidence
IT · Author affiliation · country only
Sleep Research Centre, Oasi Research Institute-IRCCS, Troina, Italy.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Isolated REM sleep behavior disorder (RBD) is an established prodromal biomarker of α-synucleinopathies. However, nearly half of Parkinson's disease patients will not exhibit iRBD or abnormal REM sleep without atonia (RSWA) at disease onset. The SYNONE skin biopsy, which detects phosphorylated α-synuclein in cutaneous nerves, provides objective evidence of pathology even in prodromal or asymptomatic stages. We describe two SYNONE-positive individuals without RSWA and markedly elevated periodic limb movement indices (PLMI >100) and mild restless legs syndrome (RLS). However, another patient with PLMI of 84 tested negative on SYN-One Test. RSWA was assessed using both conventional and automated REM atonia index scoring. To our knowledge, SYNONE-positive and RSWA-negative presentations have not been previously reported. The markedly elevated PLMI may reflect an early sign of dopaminergic dysfunction in the amygdala or spinal cord predominant disease. Longitudinal follow up and further investigation are needed to delineate spatiotemporal progression and clinical evolution.